Valneva Shareholders Approve EGM Resolutions Including the Transition to a Board of Directors
20 Dicembre 2023 - 5:45PM
Valneva Shareholders Approve EGM Resolutions Including the
Transition to a Board of Directors
Anne-Marie Graffin is appointed as Chair
of the Board of Directors
Saint-Herblain (France), December 20,
2023 –Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a
specialty vaccine company, today announced that its shareholders
approved the resolutions recommended by the Management Board at its
Extraordinary General Meeting (EGM) held on December 20, 2023.
These included the immediate transition from the Company’s two-tier
governance model to a one-tier model led by a Board of
Directors.
During a constitutional post-EGM meeting,
Valneva’s former Supervisory Board member Anne-Marie Graffin was
elected as Chair of the Company’s new Board of Directors. Ms.
Graffin is Vice Chair of Nanobiotix’s Supervisory Board, member of
the Sartorius Stedim Biotech Board of Directors and member of
Vetoquinol S.A Board of Directors. She has over 20 years of
experience in life sciences and was an Executive Committee member
at Sanofi Pasteur MSD.
In the same meeting, Thomas Lingelbach was
re-appointed as Chief Executive Officer under the new governance
model. Mr. Lingelbach will also serve on the Company’s new Board of
Directors.
Other members appointed to the Board of
Directors included members of the former Supervisory Board: James
Sulat, Dr. Kathrin Jansen, Bpifrance Participations (represented by
Maïlys Ferrère) and James Connolly. The Company intends to propose
additional Board of Directors members to its shareholders at its
Annual General Meeting in June 2024.
As previously announced1, Valneva also
established an Executive Committee which will be comprised of
members of the former Management Board including Thomas Lingelbach
(Chief Executive Officer), Peter Bühler (Chief Financial Officer),
Franck Grimaud (Chief Business Officer), Dr. Juan Carlos Jaramillo
(Chief Medical Officer), Dipal Patel (Chief Commercial Officer),
Frederic Jacotot (General Counsel), as well as Vincent Dequenne
(Chief Operating Officer). The Company plans to add a Chief People
Officer and a Chief Scientific Officer to its Executive Committee
in due course.
Anne-Marie Graffin, Chair of Valneva´s
Board of Directors, commented, “I would like to thank all
departing Supervisory Board members for their contributions and the
newly elected Board of Directors members for their trust. Together
with my fellow Board members, and the management team, we look
forward to delivering on the Company’s ambition and growth
trajectory in the interest of all our stakeholders.”
Thomas Lingelbach, Chief Executive
Officer of Valneva, commented, “I would like to express my
sincere congratulations to Anne-Marie Graffin for her appointment
as Chair of Valneva’s new Board of Directors. We are looking
forward to the new governance setting which is expected to further
improve the effectiveness and efficiency of the Company’s
leadership.”
About Valneva SEWe are a
specialty vaccine company that develops, manufactures, and
commercializes prophylactic vaccines for infectious diseases
addressing unmet medical needs. We take a highly specialized and
targeted approach, applying our deep expertise across multiple
vaccine modalities, focused on providing either first-, best- or
only-in-class vaccine solutions.
We have a strong track record, having advanced
multiple vaccines from early R&D to approvals, and currently
market two proprietary travel vaccines as well as certain
third-party vaccines leveraging our established commercial
infrastructure.
Revenues from our growing commercial business
help fuel the continued advancement of our vaccine pipeline. This
includes the world’s first vaccine against the chikungunya virus,
the only Lyme disease vaccine candidate in advanced clinical
development, which is partnered with Pfizer, as well as vaccine
candidates against the Zika virus and other global public health
threats.
Valneva
Investor and Media ContactsLaetitia Bachelot-FontaineVP
Global Communications & European Investor RelationsM +33 (0)6
4516
7099laetitia.bachelot-fontaine@valneva.com |
Joshua
Drumm, Ph.D.VP Global Investor RelationsM +001 917 815
4520joshua.drumm@valneva.com |
Forward-Looking Statements
This press release contains certain
forward-looking statements relating to the business of Valneva. In
addition, even if the actual results or development of Valneva are
consistent with the forward-looking statements contained in this
press release, those results or developments of Valneva may not be
sustained in the future. In some cases, you can identify
forward-looking statements by words such as “could,” “should,”
“may,” “expects,” “anticipates,” “believes,” “intends,”
“estimates,” “aims,” “targets,” or similar words. These
forward-looking statements are based largely on the current
expectations of Valneva as of the date of this press release and
are subject to a number of known and unknown risks and
uncertainties and other factors that may cause actual results,
performance or achievements to be materially different from any
future results, performance or achievement expressed or implied by
these forward-looking statements. In particular, the expectations
of Valneva could be affected by, among other things, uncertainties
and delays involved in the development and manufacture of vaccines,
unexpected clinical trial results, unexpected regulatory actions or
delays, competition in general, currency fluctuations, the impact
of the global and European credit crisis, and the ability to obtain
or maintain patent or other proprietary intellectual property
protection. Success in preclinical studies or earlier clinical
trials may not be indicative of results in future clinical trials.
In light of these risks and uncertainties, there can be no
assurance that the forward-looking statements made during this
presentation will in fact be realized. Valneva is providing the
information in these materials as of this press release and
disclaim any intention or obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events, or otherwise.
1 Valneva Supervisory Board Recommends Transition from a
Two-Tier Governance Model to a Board of Directors - Valneva
- 2023_12_20_VLA_Post_EGM_PR_EN_Final
Grafico Azioni Valneva (LSE:0OB3)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Valneva (LSE:0OB3)
Storico
Da Set 2023 a Set 2024